The induction and maintenance of remission are critical goals in the management of UC. However, existing therapies may not provide sufficient efficacy or patients may have trouble tolerating them.

Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Patient-reported outcomes of abdominal pain and stool frequency improved with risankizumab ...

Abivax SA ABVX on Monday shared additional Phase 3 maintenance data for investigational ulcerative colitis therapy obefazimod ...

Survival shifts in multiple myeloma: Evaluating the impact of therapeutic advances and racial disparities after a decade of change. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

Should patients with metastatic colorectal cancer (CRC) who respond to first-line treatment receive maintenance therapy or are they better off on active surveillance? In a recent trial designed to ...

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic ...